BAYRY : Summary for BAYER AG SPON ADR REP 1 NPV - Yahoo Finance

U.S. Markets close in 2 hrs 47 mins

Bayer AG (BAYRY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
99.00+1.68 (+1.73%)
As of 12:58 PM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close97.32
Bid0.00 x
Ask0.00 x
Day's Range98.23 - 99.77
52 Week Range91.53 - 128.90
Avg. Volume101,801
Market Cap83.42B
PE Ratio (TTM)16.53
Earnings DateN/A
Dividend & Yield2.87 (3.01%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters22 hours ago

    Bracco, Guerbet looking for partners for Bayer radiology bids-sources

    Italian healthcare group Bracco is working on a potential bid for the radiology supplies unit that Germany's Bayer AG is considering selling, people close to the matter said. Bracco has mandated an investment bank to find a partner for a possible joint offer for the unit, which may be valued at more than 4 billion euros (4.3 billion), they said. Bayer has not yet made a final decision on whether it will sell, but earlier this year mandated Goldman Sachs as a sellside advisor and sent out information to prospective buyers, the people said, adding that the auction had been expected to start next year.

  • American City Business Journalsyesterday

    Bayer helps Boehringer Ingelheim advance $25.5B asset swap for Merial

    Bayer AG plans to acquire a product portfolio from St. Joseph-based animal health company Boehringer Ingelheim Vetmedica Inc., the two companies jointly announced Wednesday. Once the deal is completed, Bayer would acquire BIVI's Cydectin portfolio, an anti-parasitic treatment approved for use in cattle and sheep. The deal is a further step toward Boehringer Ingelheim acquiring Merial, the animal health subsidiary of Sanofi (SNY), as part of a $25.5 billion asset swap.

  • Market Realistyesterday

    David Einhorn’s Investment Guidance at the Robin Hood Conference

    The founder and president of Greenlight Capital, David Einhorn, discussed his investment ideas at the Robin Hood Investors Conference.